Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for Recurrent Implantation Failure
NCT03161340Phase 2Completed
- Start
- Jul 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in Recurrent Implantation Failure (RIF) (2 arms). Primary endpoints: Changes in Treg cells, Changes in mRNA expression of cytokines related to Treg cells and 6 more. Started Jul 2017; status: completed.
02
Drugs
sirolimus
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT03161340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161340.